<DOC>
	<DOCNO>NCT02981524</DOCNO>
	<brief_summary>This study look objective response rate ( ORR ) measure RECIST patient mismatch repair-proficient ( MMR-p ) , advanced colorectal cancer treat CY/GVAX combination Pembrolizumab .</brief_summary>
	<brief_title>Phase 2 Study GVAX ( With CY ) Pembrolizumab MMR-p Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Documented mismatch repairproficient cancer colorectum , receive least two prior line therapy metastatic disease 2 . ECOG Performance Status 0 1 3 . Adequate organ function define studyspecified laboratory test 4 . Must use acceptable form birth control study 120 day final dose study drug 5 . Signed informed consent form 6 . Willing able comply study procedures 1 . Currently history certain studyspecified heart , liver , kidney , lung , neurological , immune medical condition 2 . Systemically active steroid use 3 . Another investigational product within 28 day prior receive study drug 4 . Major surgery significant traumatic injury ( unhealed surgical wound ) occur within 28 day prior receive study drug 5 . Chemotherapy , radiation , hormonal , biological cancer therapy within 28 day prior receive study drug 6 . Pregnant lactate 7 . Unwilling unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
</DOC>